{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:30:51Z","timestamp":1790109051474,"version":"4.0.1"},"reference-count":41,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Birth Defects Research"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Lack of available expert guidelines leads clinicians to interrupt cabergoline treatment upon confirmation of pregnancy and consider switching to bromocriptine, which is more commonly used during pregnancy but is poorly tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this review was to evaluate pregnancy outcomes, primarily major malformations and spontaneous abortions, after pregnancy exposure to cabergoline during the first trimester compared to pregnancy exposure to other comparators or no treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An Embase, Pubmed, Google Scholar, and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> search was performed. Full articles published before October 27, 2022, and evaluating the effect of cabergoline on major malformations and spontaneous abortions were considered for inclusion in the review. Search results were manually screened and selected by two independent reviewers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Totally, 2186 records were identified. After removal of duplicates and screening of abstracts, 65 full\u2010text articles were consulted. Thirty articles corresponded to our selection criteria and were included in the systematic review. This review identified 1662 pregnancies exposed to cabergoline. Most studies did not find an increased risk of congenital malformations or spontaneous abortions with cabergoline compared to other comparators or no treatment. Overall study quality was low, and there was high heterogeneity between studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This review revealed no negative impact on major malformations and spontaneous abortions of cabergoline use in pregnancy compared to other comparators or no treatment. However, additional high\u2010quality studies are needed to further study the safety of cabergoline use during pregnancy.<\/jats:p><jats:p><jats:bold>Trial Registration:<\/jats:bold> PROSPERO, CRD42021256219 (October 19, 2021)<\/jats:p><\/jats:sec>","DOI":"10.1002\/bdr2.2464","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T10:23:51Z","timestamp":1742725431000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cabergoline Use and Pregnancy Outcomes: A Systematic Review"],"prefix":"10.1002","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8360-8443","authenticated-orcid":false,"given":"Anne\u2010Sophie","family":"Otis","sequence":"first","affiliation":[{"name":"Department of Pharmacy CHU Sainte\u2010Justine  Montreal Quebec Canada"},{"name":"Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Sophie","family":"Brochet","sequence":"additional","affiliation":[{"name":"Department of Pharmacy CHU Sainte\u2010Justine  Montreal Quebec Canada"},{"name":"Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montreal Quebec Canada"},{"name":"Assisted Reproduction Technology Center, Department of Obstetrics and Gynecology CHU Sainte\u2010Justine  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3194-3688","authenticated-orcid":false,"given":"Zo\u00eb","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Department of Pharmacy CHU Sainte\u2010Justine  Montreal Quebec Canada"},{"name":"Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0783-8063","authenticated-orcid":false,"given":"Jacques","family":"Balayla","sequence":"additional","affiliation":[{"name":"Lady Davis Institute for Medical Research, Jewish General Hospital McGill University  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7247-2731","authenticated-orcid":false,"given":"Elias M.","family":"Dahdouh","sequence":"additional","affiliation":[{"name":"Assisted Reproduction Technology Center, Department of Obstetrics and Gynecology CHU Sainte\u2010Justine  Montreal Quebec Canada"},{"name":"Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology Universit\u00e9 de Montr\u00e9al  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100043\u2010112861"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012\u20103039"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/09513591003632233"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14162"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12360"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887\u2010018\u20101149\u20100"},{"key":"e_1_2_9_8_1","unstructured":"Canadian Paediatric Society.1995.\u201cPericonceptional Use of Folic Acid for Reduction of the Risk of Neural Tube Defects.\u201dSCP.https:\/\/cps.ca\/uploads\/blog_uploads\/Folic_Acid_ENG.pdf."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03343573"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1472\u20106483(10)60401\u20104"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009\u20102331"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03348017"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12370"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mefs.2018.05.001"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404\u2010013\u20102875\u2010z"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1260489"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/01443615.2020.1870944"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13048\u2010016\u20100237\u20108"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/01443615.2016.1233946"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2010014\u20100334\u20107"},{"issue":"3","key":"e_1_2_9_21_1","first-page":"207","article-title":"The Effectiveness of Cabergoline for the Prevention of Ovarian Hyperstimulation Syndrome","volume":"36","author":"Hosseini M. A.","year":"2011","journal-title":"Iranian Journal of Medical Sciences"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2010018\u20101702\u20105"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgyn.2016.04.002"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618\u2010017\u20100709\u20108"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01727477"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102265.2010.03808.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2013.07.010"},{"key":"e_1_2_9_28_1","unstructured":"Micromedex Product Information.2019.\u201cParlodel(R) Oral Tablets Oral Capsules Bromocriptine Mesylate Oral Tablets Oral Capsules.\u201dValidus Pharmaceuticals LLC (per FDA) Parsippany NJ."},{"key":"e_1_2_9_29_1","volume-title":"The Developing Human. Clinically Oriented Embryology","author":"Moore K. L.","year":"2013"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009\u20102605"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajo.13070"},{"key":"e_1_2_9_32_1","volume-title":"Apo\u2010Cabergoline Tablets","author":"Product monograph","year":"2016"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010199549020\u201000009"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2016.1254177"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0890\u20106238(02)00055\u20102"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0890\u20106238(96)00063\u20109"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102\u2010019\u201001008\u2010z"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2012.08.008"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102\u2010010\u20100243\u20106"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1055\/a\u20101468\u20104608"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5444"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mefs.2017.12.008"}],"container-title":["Birth Defects Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdr2.2464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T10:47:24Z","timestamp":1745232444000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdr2.2464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/bdr2.2464"],"URL":"https:\/\/doi.org\/10.1002\/bdr2.2464","archive":["Portico"],"relation":{},"ISSN":["2472-1727","2472-1727"],"issn-type":[{"value":"2472-1727","type":"print"},{"value":"2472-1727","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2464"}}